Amedisys, Inc. (NASDAQ:AMED) Receives $100.67 Consensus Target Price from Brokerages

Amedisys, Inc. (NASDAQ:AMED) has earned an average rating of “Hold” from the five analysts that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $100.67.

A number of research analysts recently commented on the company. William Blair cut Amedisys from an “outperform” rating to a “market perform” rating in a research report on Monday, July 1st. Cantor Fitzgerald reissued a “neutral” rating and issued a $101.00 target price on shares of Amedisys in a report on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price for the company. in a research report on Monday, July 29th.

Amedisys Stock Up 0.0 %

Shares of AMED opened at $97.17 on Friday. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30. Amedisys has a 12 month low of $89.55 and a 12 month high of $98.95. The firm’s 50 day moving average is $97.75 and its 200-day moving average is $94.59. The stock has a market capitalization of $3.18 billion, a PE ratio of -151.83, a P/E/G ratio of 1.92 and a beta of 0.78.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.10. The business had revenue of $591.19 million for the quarter, compared to the consensus estimate of $579.34 million. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. Equities research analysts forecast that Amedisys will post 4.66 EPS for the current year.

Institutional Trading of Amedisys

Several large investors have recently bought and sold shares of the business. Cetera Investment Advisers lifted its holdings in shares of Amedisys by 26.5% in the second quarter. Cetera Investment Advisers now owns 22,778 shares of the health services provider’s stock worth $2,091,000 after acquiring an additional 4,773 shares during the last quarter. Creative Planning lifted its stake in Amedisys by 7.4% in the 2nd quarter. Creative Planning now owns 4,295 shares of the health services provider’s stock valued at $394,000 after purchasing an additional 295 shares during the last quarter. Algert Global LLC bought a new position in Amedisys in the 2nd quarter valued at approximately $302,000. Murchinson Ltd. boosted its position in Amedisys by 69.2% in the second quarter. Murchinson Ltd. now owns 123,979 shares of the health services provider’s stock valued at $11,381,000 after buying an additional 50,716 shares in the last quarter. Finally, Squarepoint Ops LLC grew its stake in shares of Amedisys by 72.8% during the second quarter. Squarepoint Ops LLC now owns 64,947 shares of the health services provider’s stock worth $5,962,000 after buying an additional 27,353 shares during the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.